Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leriglitazone in Friedreich's Ataxia
NCT03917225Phase 2Completed
- Sponsor
- Minoryx Therapeutics
- Start
- Mar 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Friedreich ataxia (FA) comparing MIN-102 with Placebo (2 arms). Primary endpoint: Change from Baseline in spinal cord area cervical segment C2-C3 at 48 weeks. Started Mar 2019; status: completed.
02
Drugs
leriglitazone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT03917225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917225.